SPP100 (Tekturna/Rasilez) Reduces Left Ventricular Hypertrophy
Speedel (SWX: SPPN) welcomed promising results from the latest SPP100 (Tekturna/Rasilez[1]) surrogate marker clinical trial which were announced by Novartis and presented in a late-breaking session at the American College of Cardiology meeting in Chicago.
More: continued here
Filed under: Cardiovascular on April 2nd, 2008